A non-interventional prospective study of Early HER2-negative high-risk breast cancer and BRCA1/2 mutations prevalence in RussiA - ERA

Study identifier:D133HR00030

ClinicalTrials.gov identifier:NCT05939128

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A multicentre, single arm, non-interventional, observational, prospective study to assess the BRCA1/2m prevalence, treatment approaches and outcomes in HER2-negative high-risk early breast cancer patients in Russia

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

750

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 30 Jun 2023
Estimated Primary Completion Date: 30 Jun 2027
Estimated Study Completion Date: 30 Jun 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria